Tencent Holdings, the Chinese Internet and gaming conglomerate, and its peer NetEase (Nasdaq: NTES) jumped on Friday following Chinese government’s decision to resume game approvals. Tencent increased by 4.5% in the Hong Kong stock exchange and NetEase was up about 4% during the mid-day in Nasdaq.
A senior official of the Chinese government said in a conference on Friday that the government has started working on providing licenses for the new gaming releases. The regulatory agencies, which monitors entertainment content in China, has stopped giving licenses since March-end.
Chinese gaming firms were expected to expand internationally and M&As were expected to occur if the Chinese government continues to freeze gaming licensing. However, the recent decision by the Chinese government has given some hope for Chinese gaming companies.
Gaming industry analysts said that Tencent has lost its opportunity to generate revenue from Fortnite and PUBG games in the recent time. The Chines government wants teenagers not to get addicted to video/mobile games as their studies and health are getting affected.
According to Statista, the mobile gaming revenue in China is expected to grow from $12.54 billion in 2016 to $22.52 billion in 2022.
Even though the Chinese regulatory agencies have started the process of licensing new game releases, still they would have a severe control on the content of the games, which will be a concern for Chinese gaming companies.
We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips
Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business
Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications